Here's Why You Should Retain IRTC Stock in Your Portfolio for Now
iRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.
Zacks Investment Research9/22/2026Positive
IRTC
iRhythm Technologies IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$3.65B
P/E Ratio
—
EPS
$-0.42
Beta
1.32
52W High
$212.00
52W Low
$100.85
50-Day MA
$118.17
200-Day MA
$130.37
Dividend Yield
—
Profit Margin
-1.69%
Forward P/E
90.91
PEG Ratio
0.00
About iRhythm Technologies Inc
iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.
Fundamentals
| Revenue (TTM) | $825.34M |
| Gross Profit (TTM) | $589.74M |
| EBITDA | $17.70M |
| Operating Margin | 7.94% |
| Return on Equity | -9.63% |
| Return on Assets | 0.65% |
| Revenue/Share (TTM) | $25.43 |
| Book Value | $5.64 |
| Price-to-Book | 19.79 |
| Price-to-Sales (TTM) | 4.42 |
| EV/Revenue | 4.68 |
| EV/EBITDA | 144.00 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 20.10% |
| Shares Outstanding | $32.96M |
| Float | $30.29M |
| % Insiders | 1.17% |
| % Institutions | 110.72% |
Historical Volatility
HV 10-Day
25.08%
HV 20-Day
33.02%
HV 30-Day
46.18%
HV 60-Day
45.83%
HV Rank
50.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($176.14 target)
2
Strong Buy13
BuyLatest News
Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.
Zacks Investment Research9/4/2026Positive
iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference
SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference.
GlobeNewsWire8/26/2026Neutral
iRhythm: The Algorithmic Margin Inflection Changes The Story
iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial inflection: 20.1% revenue growth, 72.8% gross margin, and adjusted EBITDA margin expansion to 19.3%, with raised full-year guidance and record free cash flow. The ZEUS platform's FDA clearance enables significant margin leverage, reducing clinician review time by 50% and targeting $100 million in cost savings over five years.
Seeking Alpha8/21/2026Positive
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
PRNewsWire8/17/2026Neutral
iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform
IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.
Zacks Investment Research8/14/2026Positive
Here's Why iRhythm Holdings, Inc. (IRTC) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research8/14/2026Positive
iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised
IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.
Zacks Investment Research8/10/2026Positive
iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript
iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript
Seeking Alpha8/7/2026Neutral
iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates
iRhythm Holdings, Inc. (IRTC) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.32 per share a year ago.
Zacks Investment Research8/7/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IRTC and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/26/2026